These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20808270)

  • 1. [MRI evaluation of residual breast carcinoma after neoadjuvant chemotherapy].
    Morvan A; de Korvin B; Bouriel C; Carsin A; Tas P; Bendavid C; Dupré PF; Kerbrat P; Mesbah H; Poree P; Levêque J
    J Radiol; 2010 Jun; 91(6):693-9. PubMed ID: 20808270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
    Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
    Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI evaluation of residual breast cancer after neoadjuvant chemotherapy: influence of patient, tumor and chemotherapy characteristics on the correlation with pathological response.
    Diguisto C; Ouldamer L; Arbion F; Vildé A; Body G
    Anticancer Res; 2015 Jan; 35(1):581-5. PubMed ID: 25550606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
    Chen JH; Feig B; Agrawal G; Yu H; Carpenter PM; Mehta RS; Nalcioglu O; Su MY
    Cancer; 2008 Jan; 112(1):17-26. PubMed ID: 18000804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
    Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
    Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.
    Londero V; Bazzocchi M; Del Frate C; Puglisi F; Di Loreto C; Francescutti G; Zuiani C
    Eur Radiol; 2004 Aug; 14(8):1371-9. PubMed ID: 14986052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Performances of breast magnetic resonance imaging in the context of neoadjuvant chemotherapy for breast cancer to predict pathological complete response].
    Brisson C; Diguisto C; Vildé A; Body G; Arbion F; Leveque J; Ouldamer L
    J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):147-154. PubMed ID: 28403971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
    Kim HJ; Im YH; Han BK; Choi N; Lee J; Kim JH; Choi YL; Ahn JS; Nam SJ; Park YS; Choe YH; Ko YH; Yang JH
    Acta Oncol; 2007; 46(7):996-1003. PubMed ID: 17851879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
    Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
    Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.
    Bahri S; Chen JH; Mehta RS; Carpenter PM; Nie K; Kwon SY; Yu HJ; Nalcioglu O; Su MY
    Ann Surg Oncol; 2009 Jun; 16(6):1619-28. PubMed ID: 19333654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
    Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
    Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.
    Woodhams R; Kakita S; Hata H; Iwabuchi K; Kuranami M; Gautam S; Hatabu H; Kan S; Mountford C
    Radiology; 2010 Feb; 254(2):357-66. PubMed ID: 20093508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.
    Rosen EL; Blackwell KL; Baker JA; Soo MS; Bentley RC; Yu D; Samulski TV; Dewhirst MW
    AJR Am J Roentgenol; 2003 Nov; 181(5):1275-82. PubMed ID: 14573420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
    Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
    J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy.
    Belli P; Costantini M; Malaspina C; Magistrelli A; LaTorre G; Bonomo L
    Clin Radiol; 2006 Nov; 61(11):946-53. PubMed ID: 17018307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in breast cancer with three-dimensional reconstruction technique].
    Yang T; Zhang Z; Liu G; Mu D; Sun X; Chen Z; Liu Y; Wang C; Sun X; Wang Y
    Zhonghua Wai Ke Za Zhi; 2015 Apr; 53(4):280-4. PubMed ID: 26269162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy.
    Patel BK; Hilal T; Covington M; Zhang N; Kosiorek HE; Lobbes M; Northfelt DW; Pockaj BA
    Ann Surg Oncol; 2018 May; 25(5):1350-1356. PubMed ID: 29516362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
    Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
    Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
    Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
    Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
    Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.